Commenting on the firm's achievements, Dr Singh says, "Imgenex India has developed the capability of producing about 100 monoclonal antibodies and 400 polyclonal antibodies per year under GLP condition making it one of the largest antibody manufacturing companies in India."

Imgenex is also working on developing novel monoclonal antibodies against cancer and autoimmune diseases and therapeutic biosimilar monoclonal antibodies. Dr Singh expects that with funding from the DBT or partnership with pharmaceutical companies, the company would be able to complete its osteoporosis and biosimilar programs. "Our future goal is to develop biosimilars as well as innovative drugs at affordable cost for patients in India and the neighboring countries," he says.

On receiving the BioSpectrum Emerging Company of the Year Award, Dr Singh says, "It is a pleasant surprise. On behalf of the Imgenex team, I thank BioSpectrum for choosing us as the 3^rd BioSpectrum Asia-Pacific Emerging Company of the Year Award. I hope this award will encourage young entrepreneurs in Asia-Pacific countries to live their dream of starting a successful biotech company."